To continue getting breaking news and the full stories from The Boston Globe, subscribe today.

The Boston Globe

Business

Boston.com

Biogen Idec submits FDA application for MS drug

By Chris Reidy

 |  Globe Staff  

  February 28, 2012

Biogen Idec Inc., a Weston-based biotechnology company known for its multiple sclerosis drugs, said it has submitted a New Drug Application to federal regulators to get approval to market a potential new MS treatment known as BG-12. In December, Biogen Idec shares hit their high for 2011 when the company released promising results from a clinical trial of BG-12. BG-12 would be taken twice a day in pill form, and it is designed to treat the most common form of MS.

Stay with the story. Get full access to BostonGlobe.com for just 99¢

Unlimited access to BostonGlobe.com for only 99¢ for the first 4 weeks. You can cancel at any time.

  • The FULL story all day: Enjoy all of the high-quality, in-depth journalism in the print edition of the Boston Globe — plus breaking news that's updated 24/7.
  • A truly reader-friendly format: It's online news that looks and reads just like the newspaper — uncluttered, uninterrupted.
  • Breakthrough technology: The responsive design automatically adapts content so it always reads perfectly on the digital device of your choice.
Get started today

Free access for home delivery subscribers.

Just need to link your home delivery account; one easy step.

Link my home delivery account

BostonGlobe.comSubscriber Log In

Contact us for help